315 related articles for article (PubMed ID: 25752548)
1. Japanese universal health care faces a crisis in cancer treatment.
Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
[No Abstract] [Full Text] [Related]
2. Health policy: Putting a price on cancer.
Sullivan R; Aggarwal A
Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
[No Abstract] [Full Text] [Related]
3. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
[No Abstract] [Full Text] [Related]
4. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
Pfundner H
MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
[No Abstract] [Full Text] [Related]
5. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
6. [Clinical studies in oncology--a challenge for clinical and academic pathology].
Röcken C
Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
[No Abstract] [Full Text] [Related]
7. Resistance and change: a multiple streams approach to understanding health policy making in Ghana.
Kusi-Ampofo O; Church J; Conteh C; Heinmiller BT
J Health Polit Policy Law; 2015 Feb; 40(1):195-219. PubMed ID: 25480850
[TBL] [Abstract][Full Text] [Related]
8. [The health care debate in USA hits the core of the American self comprehension].
Skau M
Ugeskr Laeger; 2009 Oct; 171(44):3150. PubMed ID: 19866510
[No Abstract] [Full Text] [Related]
9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
10. [Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective].
Fukuda A; Igarashi A
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1311-1315. PubMed ID: 27899770
[TBL] [Abstract][Full Text] [Related]
11. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
12. Dialog between JHA (Japan Hospital Association) and IHF (International Hospital Federation).
Akiyama H; Nara M; Hoshi K; Barron JP
Jpn Hosp; 1999 Jul; (18):13-22. PubMed ID: 11184919
[No Abstract] [Full Text] [Related]
13. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
Götte D
Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
[TBL] [Abstract][Full Text] [Related]
14. Prospects for health in Mexico after the presidential election.
Woodman S
Lancet; 2018 Jul; 392(10142):107. PubMed ID: 30017118
[No Abstract] [Full Text] [Related]
15. The era of cancer discovery.
Cantley LC; Baselga J
Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
[No Abstract] [Full Text] [Related]
16. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
[No Abstract] [Full Text] [Related]
17. Cancer Drugs Fund of minimal benefit.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
[No Abstract] [Full Text] [Related]
18. Getting to universal coverage with better safety-net programs for the uninsured.
Hall MA
J Health Polit Policy Law; 2011 Jun; 36(3):521-6. PubMed ID: 21673257
[No Abstract] [Full Text] [Related]
19. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
20. Demand grows for early access to promising cancer drugs.
Baldwin J
J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
